REG - ValiRx PLC - Result of AGM

ValiRxAnnouncement

23/07/2020 13:00

RNS Number : 9216T
  
ValiRx PLC
  
23 July 2020
  
 

 
 
 
VALIRX PLC
("ValiRx", the "Company" or the "Group")
 
Result of AGM
 
ValiRx Plc (AIM: VAL) announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
 
The proxy votes are set out below:-
 



Resolutions


For


Against


Discretion




Resolution 1 - Receive the annual report and accounts


4,612,178


0


2,000




Resolution 2 - Re-appoint Gerry Desler as a director


4,226,311


377,739


2,000




Resolution 3 - Re-appoint Dr Suzanne Dilly as a director


4,579,542


23,437


2,000




Resolution 4 - Re-appoint Martin Lampshire as a director


4,579,542


24,623


2,000




Resolution 5 - Re-appoint Dr Kevin Cox as a director


4,580,958


23,207


2,000




Resolution 6 - Re-appoint the auditors


4,573,342


26,058


2,000




Resolution 7 - Set the auditors' remuneration


4,548,033


49,943


2,000




Resolution 8 - Provide authority to allot share capital


4,441,339


62,857


2,008




Resolution 9 - Provide authority to dis-apply statutory pre-emption rights (Special Resolution)


4,436,339


67,857


2,008



 
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
*** ENDS ***
 
For more information, please contact:
 



ValiRx plc


Tel: +44 (0) 20 7073 2628
www.valirx.com




Suzanne Dilly


Suzanne.Dilly@valirx.com




Cairn Financial Advisers LLP (Nominated Adviser) 
Liam Murray / Jo Turner / Ludovico Lazzaretti


Tel: +44 (0) 20 7213 0880




Peterhouse Capital Limited (Sole Broker)
Duncan Vasey / Lucy Williams / Eran Zucker 


Tel: +44 (0) 20 7469 0930



 
 
Notes for Editors
 
About ValiRx 
 
ValiRx PLC accelerates the development of innovative medicines that enhance patient experience.  We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.
 
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
RAGSEDFFDESSEIW